Hemophilia B Gene Therapy in Mice Using a Novel Chimeric AAV Capsid Combined with a Potency Enhanced FIX Variant

Time: 2:45 pm
day: Day One


  • Advantages of next generation AAV capsids combined with transgenes having increased functionality to lower vector doses
  • Developing a novel AAV vector technology to reduce systemic payload of hemophilia B gene therapies
  • Discussing pre-clinical data on the performance of the novel technology